Victhom Human Bionics Inc. Files First Default Status Report



    /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
    INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
    DISSEMINATION IN THE UNITED STATES./

    QUEBEC, April 15 /CNW Telbec/ - Victhom Human Bionics Inc. (("Victhom")
(TSX: VHB)) is providing its first biweekly Default Status Report under
National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults
("NP 12-203"). On April 1, 2009, Victhom announced that its audited annual
financial statements, CEO and CFO certification, management discussion and
analysis ("MD&A") and annual information form ("AIF") for the year ended
December 31, 2008 would not be released as required by March 31, 2009.
    In accordance with NP 12-203 and as previously announced, Victhom has
voluntarily requested that the Autorité des marchés financiers and other
Canadian securities regulatory authorities issue a temporary order that
prohibits certain directors, officers and insiders of Victhom from trading in
securities of Victhom for as long as the annual financial statements, CEO and
CFO certifications and related MD&A and AIF are not filed (the "Management
Cease Trade Order").
    Discussions are still ongoing with the objective to complete, in the
short term, a transaction to allow Victhom to continue its research and
development activities. Victhom still anticipates that the release of the
annual financial statements, CEO and CFO certifications and related MD&A and
AIF will occur no later than April 30, 2009.
    Victhom reports that since announcing the Management Cease Order of April
1, 2009, there have not been any material changes to the information contained
therein; nor any failure by Victhom to fulfill its intentions as stated
therein with respect to satisfying the provisions of the alternative
information guidelines, and there are no additional defaults or anticipated
defaults subsequent to such announcement. Further, there have been no
additional material changes respecting Victhom and its affairs. Victhom
intends to file, if required, its next Default Status Report by April 29,
2009.

    About Victhom

    Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix division focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix division develops biomechatronic
products to support or replace peripheral limbs in what is known as the
orthotics and prosthetics market.

    FORWARD-LOOKING STATEMENTS

    Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
statements.




For further information:

For further information: Normand Rivard, Acting President and Chief
Financial Officer, Victhom Human Bionics Inc., (418) 872-5665, Fax: (418)
864-7034, normand.rivard@victhom.com, www.victhom.com

Organization Profile

Victhom Human Bionics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890